Skip to content

AUBAGIO 14 mg film-coated tablets

DRUG7 trials

Sponsors

F. Hoffmann-La Roche AG, Antwerp University Hospital, Sanofi-Aventis Research & Development, Sanofi-Aventis Recherche & Developpement, Les Hopitaux Universitaires De Strasbourg

Conditions

Multiple SclerosisNervous system diseasesProgressive Multiple SclerosisRelapsing multiple sclerosis (RMS)multiple sclerosis

Phase 2

Phase 3

An interventional, Phase 3 extension study to investigate long-term safety and tolerability of tolebrutinib in participants with relapsing multiple sclerosis, primary progressive multiple sclerosis, or nonrelapsing secondary progressive multiple sclerosis
WithdrawnCTIS2023-503631-18-00
Sanofi-Aventis Research & DevelopmentNervous system diseases
Target: 75Updated: 2023-11-27
Randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis
RecruitingCTIS2023-504358-36-00
Sanofi-Aventis Recherche & Developpementmultiple sclerosis
Start: 2024-10-17Target: 386Updated: 2026-01-10
An interventional, Phase 3 extension study to investigate long-term safety and tolerability of tolebrutinib in participants with relapsing multiple sclerosis, primary progressive multiple sclerosis, or nonrelapsing secondary progressive multiple sclerosis
Active, not recruitingCTIS2023-503631-18-01
Sanofi-Aventis Recherche & DeveloppementNervous system diseases
Start: 2024-05-20Target: 1405Updated: 2025-11-11
A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
Active, not recruitingCTIS2022-502609-14-00
F. Hoffmann-La Roche AGRelapsing multiple sclerosis (RMS)
Start: 2020-12-09Target: 214Updated: 2026-01-23
DISEASE MODIFYING THERAPIES WITHDRAWAL IN INACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS AGED 55 AND OVER: A MULTICENTRIC, RANDOMIZED, CONTROLLED, OPEN-LABEL CLINICAL TRIAL - TWINS
RecruitingCTIS2024-513475-41-00
Les Hopitaux Universitaires De StrasbourgMultiple Sclerosis
Start: 2025-02-03Target: 200Updated: 2024-11-08
Randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis
RecruitingCTIS2024-514343-29-00
Sanofi-Aventis Recherche & Developpementmultiple sclerosis
Start: 2024-11-19Target: 410Updated: 2026-01-10

Related Papers